Affiliation:
1. Institute of Laboratory Medicine , Hospital of the University of Munich (LMU) , Marchioninistr. 15 , 81377 Munich , Germany
Abstract
Abstract
In view of the role of pharmacotherapy in medicine, on the one hand, and the powerful technical possibilities that are now available on the other hand, therapeutic drug monitoring is a surprisingly neglected area of laboratory medicine. In this viewpoint article, an “omics approach” to pharmacovigilance and drug monitoring is proposed and discussed. A realistic goal for laboratory medicine in the 21st century should indeed be to enable clinicians to check whether the right drug is present in the right patient with an appropriate blood concentration for each compound.
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference7 articles.
1. Vogeser M, Zhang V. Understanding the strategic landscape surrounding the implementation of mass spectrometry in the clinical laboratory: a SWOT analysis. Clin Mass Spectrom 2018;9:1–6.
2. Wong JW, Wang J, Zhan K, Hayward G, Wittenberg JG. Pesticides: an update on mass spectrometry approaches. In: Encyclopedia Food Chemistry. Amsterdam, The Netherlands: Elsevier, 2019:433–8.
3. Zander J, Paal M, Vogeser M. The role of mass spectrometry in antibiotic stewardship. Clin Mass Spectrom 2019;14:31–3.
4. Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2019;10:1662.
5. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 2019;21:25.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献